Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer...
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Background
Patients with triple negative breast cancer (TNBC) exhibit poor prognosis and are at high risk of tumour relapse, due to the resistance to chemotherapy. These aggressive phenotypes are in part attributed to the presence of breast cancer stem cells (BCSCs). Therefore, targeting BCSCs is a priority to overcoming chemotherapy failure in...
Alternative Titles
Full title
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2154246791
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2154246791
Other Identifiers
ISSN
0007-0920,1532-1827
E-ISSN
1532-1827
DOI
10.1038/s41416-018-0287-3
